drug

LY4086940

1 story · latest Oct 22, 2026

Follow LY4086940. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Eli Lilly

Timeline

Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trials

Oct 22Weekly roundup, 11 itemscetuximab dulaglutide

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.